Last reviewed · How we verify
Joycle (diclofenac etalhyaluronate sodium)
Joycle (generic name: diclofenac etalhyaluronate sodium) is a drug developed by Seikagaku Corporation. It is currently FDA-approved for Osteoarthritis of hip, Osteoarthritis of knee.
At a glance
| Generic name | diclofenac etalhyaluronate sodium |
|---|---|
| Sponsor | Seikagaku Corporation |
| Target | Prostaglandin E2 receptor EP2 subtype |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Osteoarthritis of hip
- Osteoarthritis of knee
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Joycle CI brief — competitive landscape report
- Joycle updates RSS · CI watch RSS
- Seikagaku Corporation portfolio CI
Frequently asked questions about Joycle
What is Joycle?
Joycle (diclofenac etalhyaluronate sodium) is a pharmaceutical drug developed by Seikagaku Corporation, indicated for Osteoarthritis of hip, Osteoarthritis of knee.
What is Joycle used for?
Joycle is indicated for Osteoarthritis of hip, Osteoarthritis of knee.
Who makes Joycle?
Joycle is developed and marketed by Seikagaku Corporation (see full Seikagaku Corporation pipeline at /company/seikagaku-corporation).
What is the generic name of Joycle?
diclofenac etalhyaluronate sodium is the generic (nonproprietary) name of Joycle.
What development phase is Joycle in?
Joycle is FDA-approved (marketed).
What does Joycle target?
Joycle targets Prostaglandin E2 receptor EP2 subtype.
Related
- Target: All drugs targeting Prostaglandin E2 receptor EP2 subtype
- Manufacturer: Seikagaku Corporation — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Osteoarthritis of hip
- Indication: Drugs for Osteoarthritis of knee
- Compare: Joycle vs similar drugs
- Pricing: Joycle cost, discount & access